Factors Predicting Adverse Events Associated with Pregabalin Administered for Neuropathic Pain ReliefReportar como inadecuado




Factors Predicting Adverse Events Associated with Pregabalin Administered for Neuropathic Pain Relief - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Pain Research and Management - Volume 19 2014, Issue 6, Pages e164-e167

Original Article

Departments of Hospital Pharmacy, Graduate School of Medical Science, Kyoto, Japan

Pain Treatment and Palliative Care Unit, University Hospital, Graduate School of Medical Science, Kyoto, Japan

Departments of Anesthesiology, Graduate School of Medical Science, Kyoto, Japan

Pain Management and Palliative Care Medicine, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan



Copyright © 2014 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

BACKGROUND:Pregabalin administration is occasionally abandoned due to adverse events such as somnolence, dizziness, unsteadiness, weight gain and edema. However, the exact causes of these differences in adverse events associated with pregabalin have not been elucidated.

OBJECTIVE: To identify factors predicting adverse events associated with pregabalin administered for neuropathic pain.

METHODS: The present study was a retrospective analysis involving 208 patients with neuropathic pain who had been treated with pregabalin in the pain clinic at the authors’ hospital between July 2010 and September 2011. Variables were extracted from the clinical records for regression analysis of factors related to the occurrence of adverse events associated with pregabalin administration. Multivariate logistic regression analysis was used to examine the relationship between various predictive factors and the adverse events.

RESULTS: Predictive factors were: duration of therapy OR 1.684 95% CI 1.179 to 2.406; P=0.0042 for somnolence; nonsteroidal anti-inflammatory drugs OR 0.132 95% CI 0.030 to 0.578; P=0.0072, age OR 3.137 95% CI 1.220 to 8.066; P=0.0177 and maintenance dose OR 0.437 95% CI 0.217 to 0.880; P=0.0205 for unsteadiness; serum creatinine OR 6.439 95% CI 1.541 to 26.902; P=0.0107 for body weight gain; and neurotropin OR 8.538 95% CI 1.159 to 62.901; P=0.0353 and serum creatinine OR 6.912 95% CI 1.118 to 42.726; P=0.0375 for edema.

CONCLUSIONS: The results of the present study indicate that care is warranted regarding long durations of therapy for somnolence, advanced age rather than dose-dependent adverse events for unsteadiness, elevated serum creatinine level for weight gain, and elevated serum creatinine level and combination use of neurotropin for edema. The safety of the combined use of pregabalin and nonsteroidal anti-inflammatory drugs were also suggested.





Autor: Yuko Kanbayashi, Keiko Onishi, and Toyoshi Hosokawa

Fuente: https://www.hindawi.com/



DESCARGAR PDF




Documentos relacionados